Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Biothera begins dosing in Imprime PGG and cetuximab combination Phase III trial for colorectal cancer

Biothera begins dosing in Imprime PGG and cetuximab combination Phase III trial for colorectal cancer

Oak Point students raise $42,474.24 to combat cancer

Oak Point students raise $42,474.24 to combat cancer

JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia

JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia

Cytonet receives FDA orphan drug designation for liver cell infusion to treat urea cycle disorders

Cytonet receives FDA orphan drug designation for liver cell infusion to treat urea cycle disorders

Cellular 'mechanic' keeps DNA damage in check in cells

Cellular 'mechanic' keeps DNA damage in check in cells

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

Over-activation of single gene promotes leukemia, but its loss causes liver cancer

Over-activation of single gene promotes leukemia, but its loss causes liver cancer

CytRx sells global rights of molecular chaperone assets to Orphazyme

CytRx sells global rights of molecular chaperone assets to Orphazyme

PGT, Quintiles collaborate to bring genomic testing into mainstream drug development

PGT, Quintiles collaborate to bring genomic testing into mainstream drug development

EntreMed reports net loss of $2.6 million for first quarter 2011

EntreMed reports net loss of $2.6 million for first quarter 2011

New lenalidomide phase III study data presented at 13th International Myeloma Workshop

New lenalidomide phase III study data presented at 13th International Myeloma Workshop

Researchers untangle two distinct ways in which tumor-suppressor protein works

Researchers untangle two distinct ways in which tumor-suppressor protein works

New study sheds light on origins of myeloid leukemia

New study sheds light on origins of myeloid leukemia

Trillium raises $1 million to advance TTI-1612 into clinical trials for interstitial cystitis treatment

Trillium raises $1 million to advance TTI-1612 into clinical trials for interstitial cystitis treatment

Tosedostat and OPAXIO study results to be presented at ASCO Annual Meeting

Tosedostat and OPAXIO study results to be presented at ASCO Annual Meeting

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

Inovio first quarter total revenue increases to $3.1 million for 2011

Inovio first quarter total revenue increases to $3.1 million for 2011

Zebrafish research identifies undiscovered high-risk genetic features in T-cell acute lymphocytic leukemia

Zebrafish research identifies undiscovered high-risk genetic features in T-cell acute lymphocytic leukemia

16-year-old uses supercomputing network to invent new drug cocktail for cystic fibrosis

16-year-old uses supercomputing network to invent new drug cocktail for cystic fibrosis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.